Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Nov 10;4(10):1030-1033.
doi: 10.1016/j.jdcr.2018.08.014. eCollection 2018 Nov.

Ustekinumab-associated disseminated verrucae

Mary E Anderson  1 , Dawn Queen  2 , Stephen L Vance  3 , Larisa J Geskin  3
Affiliations
Case Reports

Ustekinumab-associated disseminated verrucae

Mary E Anderson et al. JAAD Case Rep. .
No abstract available

Keywords: APC, antigen presenting cell; HPV, human papilloma virus; IFN, interferon; IL, interleukin; PDT, photodynamic therapy; TNF, tumor necrosis factor; Th, helper T cell; biologics; immunosuppression; psoriasis; ustekinumab; verrucae.

PubMed Disclaimer

Figures

Fig 1
Fig 1
A, Disseminated verrucae: multiple pink to skin-colored papules in a scattered distribution over the bilateral lower extremities. B, Patient after 3 PDT cycles: significant improvement in the number and size of verrucous lesions.
Fig 2
Fig 2
Schematic representation of the intersection between HPV infection and IL-12/IL-23 pathway. (A) Cell-mediated clearance of virally infected cells begins with APCs encountering viral antigen. (B) APCs engulf antigen and present to immature naïve T cells via MHC class I molecules. (C) T cells are activated by IL-12 and IL-23 cytokines and differentiate into Th1 and Th17 cells. Th1 cells (D) stimulate proliferation of B cells capable of (E) producing opsonizing antibodies, (F) activating macrophages, and (G) stimulating proliferation of cytotoxic T cells. (H) Cytotoxic T cells, activated macrophages, and opsonizing antibodies work together to recognize and eliminate virally infected epithelial cells.
See this image and copyright information in PMC

References

    1. Griffiths C.E., Strober B.E., van de Kerkhof P., ACCEPT Study Group Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128. - PubMed
    1. Galloway J.B., Hyrich K.L., Mercer L.K., BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50(1):124–131. - PMC - PubMed
    1. Koc E., Tunca M., Arda E. Multiple widespread warts due to etanercept treatment in a psoriatic patient: a case report. J Turk Acad Dermatol. 2008;2(1):82103c.
    1. Leonardi C.L., Kimball A.B., Papp K.A. Efficacy and safety of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet. 2008;371:1665–1674. - PubMed
    1. Papp K.A., Griffiths C.E., Gordon K., PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854. - PubMed

Publication types

LinkOut - more resources